检索结果 - Michael Schlichting

  • Showing 1 - 9 results of 9
Refine Results
  1. 1
    Use of Early Tumor Shrinkage to Predict Long-Term Outcome in Metastatic Colorectal Cancer Treated With Cetuximab

    Use of Early Tumor Shrinkage to Predict Long-Term Outcome in Metastatic Colorectal Cancer Treated With Cetuximab 由 Hubert Piessevaux, Marc Buyse, Michael Schlichting, Eric Van Cutsem, Carsten Bokemeyer, S. Heeger, Sabine Tejpar

    出版 2013
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  2. 2
    Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials

    Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials 由 Carsten Bokemeyer, Eric Van Cutsem, Philippe Rougier, Fortunato Ciardiello, S. Heeger, Michael Schlichting, İlhan Çelik, Claus‐Henning Köhne

    出版 2012
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  3. 3
    Programmed Death-Ligand 1 Immunohistochemistry Assay Comparison Studies in NSCLC: Characterization of the 73-10 Assay

    Programmed Death-Ligand 1 Immunohistochemistry Assay Comparison Studies in NSCLC: Characterization of the 73-10 Assay 由 H. Grote, Zheng Feng, Michael Schlichting, Christoph Helwig, Mary Ruisi, Hulin Jin, Juergen Scheuenpflug, Claudia-Nanette Gann, Zhen Su, Martin Reck, Everett E. Vokes, Keith M. Kerr

    出版 2020
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  4. 4
    Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor <i>KRAS</i> and <i>BRAF</i> Mutation Status

    Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor <i>KRAS</i... 由 Eric Van Cutsem, Claus-Henning Köhne, István Láng, Gunnar Folprecht, Marek P. Nowacki, Stefano Cascinu, I. Shchepotin, Joan Maurel, David Cunningham, Sabine Tejpar, Michael Schlichting, Angela Zubel, İlhan Çelik, Philippe Rougier, Fortunato Ciardiello

    出版 2011
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  5. 5
    Intrapatient Cetuximab Dose Escalation in Metastatic Colorectal Cancer According to the Grade of Early Skin Reactions: The Randomized EVEREST Study

    Intrapatient Cetuximab Dose Escalation in Metastatic Colorectal Cancer According to the Grade of Early Skin Reactions: The Randomized EVEREST Study 由 Eric Van Cutsem, Sabine Tejpar, Dirk Vanbeckevoort, Marc Peeters, Yves Humblet, Hans Gelderblom, Jan B. Vermorken, F. Viret, Bengt Glimelius, Elisa Gallerani, Alain Hendlisz, Annemieke Cats, Markus Moehler, Xavier Sagaert, Soetkin Vlassak, Michael Schlichting, Fortunato Ciardiello

    出版 2012
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  6. 6
    Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Analyses of Patient-reported Outcomes and Quality-adjusted Time Without Symptoms or Toxicity from the JAVELIN Bladder 100 Trial

    Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Analyses of Patient-reported Outcomes and Quality-adjusted Time Without Symptoms or Toxicity from the J... 由 Petros Grivas, Jeanny B. Aragon‐Ching, Joaquim Bellmunt, Yohann Loriot, Miguel Á. Climent Durán, Srikala S. Sridhar, Po‐Jung Su, Se Hoon Park, Evgeny Kopyltsov, Yoshiaki Yamamoto, Natalia Jacob, Jason Hoffman, Karin Tyroller, Juliane Manitz, Mairead Kearney, Michael Schlichting, Thomas Powles

    出版 2025
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  7. 7
    Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

    Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer 由 Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre, J. Załuski, Chung-Rong Chang Chien, Anatoly Makhson, Geert D’Haens, Tamás Pintér, Robert Lim, G. Bodoky, Jae Kyung Roh, Gunnar Folprecht, Paul Ruff, Christopher Stroh, Sabine Tejpar, Michael Schlichting, Johannes Nippgen, Philippe Rougier

    出版 2009
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  8. 8
    Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

    Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study 由 Andrea B. Apolo, Jeffrey R. Infante, Ani Sarkis Balmanoukian, Manish R. Patel, Ding Wang, Karen Kelly, Anthony Mega, Carolyn D. Britten, Alain Ravaud, Alain C. Mita, Howard Safran, Thomas E. Stinchcombe, Marko Srdanov, Arnold B. Gelb, Michael Schlichting, Kevin M. Chin, James L. Gulley

    出版 2017
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  9. 9
    Single-cell chromatin accessibility identifies pancreatic islet cell type– and state-specific regulatory programs of diabetes risk

    Single-cell chromatin accessibility identifies pancreatic islet cell type– and state-specific regulatory programs of diabetes risk 由 Joshua Chiou, Chun Zeng, Cheng Zhang, Jee Yun Han, Michael Schlichting, Michael Miller, Robert Mendez, Serina Huang, Jinzhao Wang, Yinghui Sui, Allison Deogaygay, Mei-Lin Okino, Yunjiang Qiu, Ying Sun, Parul Kudtarkar, Rongxin Fang, Sebastian Preißl, Maike Sander, David U. Gorkin, Kyle J. Gaulton

    出版 2021
    获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: